Click here to register.
Download the 2009 announcement here.
Submit an
abstract here.
2010 conference information coming soon!
Save the date:
December 9-12, 2010
Hollywood, Florida
The Westin Diplomat
Dear Colleague,
The 2009 Advances in IBD conference was an unquestionable success! Overall, the consensus was that this meeting has become a “can’t miss” update for those who study and manage patients with inflammatory bowel diseases.
More than 1,100 gastroenterologists, pediatric specialists, clinical researchers, nurses, and other healthcare professionals with an interest in the treatment of patients with IBD participated in the scientific agenda. 49 international expert specialists offered more than 80 education presentations, and 174 abstracts were accepted for oral or poster presentation.
Be sure to note the abstract award winners listed on the Accepted Abstracts and Award Winners page of this website. Congratulations to all!
The scientific agenda featured a robust array of topics. Some highlights included:
- Important basic science pearls for the clinician managing patients with IBD:
– Patients with IL-10 receptor mutations develop early aggressive Crohn’s disease
– Genes in the IL-23/IL-17 pathway interact to increase Crohn’s disease susceptibility - New biologics in development showing promise in phase III trials could lead to expansion of approved agents for the clinician over the next 1-2 years
– Vedolizumab, ustekinumab, ABT-874, and sargramostim - Introduction to quality of care for IBD was very timely considering the current healthcare/CME environment. Important points discussed included:
– How to offer a uniform high level of care to all patients
– How quality of care will affect reimbursement
– What are the indicators of high quality of care with regard to medical therapy?
– Existing movements within the IBD arena toward improvements in quality of care from the AGA, pediatric IBD community and CCFA - State-of-the-art advances in endoscopy for detecting colonic dysplasia
- Important clinical research questions in IBD:
– Can we develop reliable predictors of disease relapse?
– The optimal endpoints for medical therapy in UC and CD
– Can early aggressive intervention soon after diagnosis change the course of disease, with withdrawal of very potent therapy and maintenance of long-term benefit off of medication?
– How do the trade-offs between the potential for additional efficacy and safety concerns of combination therapy balance out?
Some of the attendees summed it up this way:
“The scientific meeting is the best!!”
“I truly look forward to this conference and reserve space in my calendar for it each year.”
“Comprehensive and enjoyable! Definitely one of the best I have attended!”
“EXCELLENT PROGRAM – I plan to be back”
We hope to see you in December, 2010!
This meeting is endorsed by the American College of Gastroenterology
